SCHEMBL1887368

SCHEMBL1887368

CN(C)c1ccc(C(=O)Nc2n[nH]c3c2CN(S(=O)(=O)c2cccnc2)CC3(C)C)c(NC(=O)c2ccc[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.46
CDK2 P24941 4/20 0.37
CCNA2 P20248 3/20 0.37
CCNA1 P78396 3/20 0.37
NTRK1 P04629 7/20 0.37
HDAC1 Q13547 1/20 0.36
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
GFER P55789 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PRKCB P05771 2/20 0.32
CCNE2 O96020 1/20 0.32
CCNE1 P24864 1/20 0.32
GSK3B P49841 1/20 0.32
PAK4 O96013 1/20 0.32
MET P08581 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893061 0.90 IGF1R (0.45) IGF1RCDK2CCNA2CCNA1NTRK1
SCHEMBL1888534 0.89 IGF1R (0.46) IGF1RCDK2CCNA2CCNA1NTRK1
SCHEMBL1889265 0.89 IGF1R (0.58) IGF1RCDK2CCNA2CCNA1NTRK1
SCHEMBL2679281 0.87 CDK2 (0.41) CDK2CCNA2CCNA1NTRK1HDAC1
SCHEMBL2458213 0.86 IGF1R (0.54) IGF1RCDK2CCNA2CCNA1NTRK1
SCHEMBL1890579 0.86 IGF1R (0.62) IGF1RHDAC1CHRNB2CHRNA4GAA
SCHEMBL2679278 0.86 CDK2 (0.42) CDK2CCNA2CCNA1NTRK1HDAC1
SCHEMBL1894745 0.84 IGF1R (0.43) IGF1RCDK2CCNA2CCNA1NTRK1
SCHEMBL1890513 0.82 IGF1R (0.56) IGF1RCDK2CCNA2CCNA1NTRK1
SCHEMBL1894271 0.82 IGF1R (0.55) IGF1RCDK2CCNA2CCNA1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US claimed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885CDK2 91/4885CCNA2 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.